Proteomic analysis suggests that lab-grown beef has a different allergen profile than conventional meat, with potential implications for individuals with alpha-gal syndrome.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from a pre-specified Week 36 interim ...

US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) has reported positive Phase III data for povetacicept in immunoglobulin A nephropathy, strengthening the company’s case for accelerated approval from ...

Vertex reported a phase 3 win for its kidney disease prospect povetacicept, meeting analyst expectations and firing the starting gun on a race to the FDA that could result in an accelerated approval ...

Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetaciceptin IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the ...

Shares of Vertex Pharmaceuticals Incorporated (VRTX) rose as much as 7% after hours on Monday after the company announced ...

Vertex Pharmaceuticals Inc VRTX shares are rising in extended trading Monday after the company announced positive interim results for one of its Phase 3 trials. Vertex Pharmaceuticals stock is trading ...

The emergence of alpha-gal syndrome last fall on Block Island has caused the Town of New Shoreham to renew its focus on greatly reducing or eliminating the deer herd on Block Island. While Lyme ...

A NOVEL therapeutic approach targeting the cytokine A Proliferation-Inducing Ligand (APRIL) may significantly reduce proteinuria and disease activity in patients with IgA nephropathy, according to ...

Povetacicept significantly reduced proteinuria in patients with IgA nephropathy in the RAINIER trial, supporting an upcoming FDA submission.